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Abstract
Background: Diabetic kidney disease (DKD) remains one of the leading causes of premature death in diabetes.
DKD is classified on albuminuria and reduced kidney function (estimated glomerular filtration rate (eGFR)) but these
have modest value for predicting future renal status. There is an unmet need for biomarkers that can be used in
clinical settings which also improve prediction of renal decline on top of routinely available data, particularly in the
early stages. The iBEAt study of the BEAt-DKD project aims to determine whether renal imaging biomarkers
(magnetic resonance imaging (MRI) and ultrasound (US)) provide insight into the pathogenesis and heterogeneity
of DKD (primary aim) and whether they have potential as prognostic biomarkers in DKD (secondary aim).
Methods: iBEAt is a prospective multi-centre observational cohort study recruiting 500 patients with type 2 diabetes
(T2D) and eGFR ≥30ml/min/1.73m2. At baseline, blood and urine will be collected, clinical examinations will be
performed, and medical history will be obtained. These assessments will be repeated annually for 3 years. At baseline
each participant will also undergo quantitative renal MRI and US with central processing of MRI images. Biological
samples will be stored in a central laboratory for biomarker and validation studies, and data in a central data depository.
Data analysis will explore the potential associations between imaging biomarkers and renal function, and whether the
imaging biomarkers improve the prediction of DKD progression. Ancillary substudies will: (1) validate imaging biomarkers
against renal histopathology; (2) validate MRI based renal blood flow measurements against H2O
15 positron-emission
tomography (PET); (3) validate methods for (semi-)automated processing of renal MRI; (4) examine longitudinal changes
in imaging biomarkers; (5) examine whether glycocalyx and microvascular measures are associated with imaging
biomarkers and eGFR decline; (6) explore whether the findings in T2D can be extrapolated to type 1 diabetes.
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Discussion: iBEAt is the largest DKD imaging study to date and will provide valuable insights into the progression and
heterogeneity of DKD. The results may contribute to a more personalised approach to DKD management in patients
with T2D.
Trial registration: Clinicaltrials.gov (NCT03716401).
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Background
The BEAt-DKD project
Diabetic kidney disease (DKD) is the leading cause of
end stage renal disease [1, 2]. It is currently estimated
that approximately 20–40% of people with diabetes will
develop DKD [3], and this is expected to rise in the fu-
ture. With the global increase in the prevalence of dia-
betes [4], particularly type 2 diabetes (T2D), DKD is
reaching epidemic proportions, with health and quality
of life implications (e.g. increased risk of cardiovascular
mortality) for the individual [5]. Even with current ap-
proaches for the management of diabetes and renin-
angiotensin-aldosterone system blockade, there is still a
large residual risk in DKD [6].
DKD is routinely classified clinically based on albumin-
uria and reduced kidney function (estimated glomerular
filtration rate (eGFR)). Albuminuria is traditionally viewed
as a hallmark of diabetes related kidney damage. However,
there are limitations of using albuminuria to classify DKD,
which include the need for multiple measurements to
mitigate spurious results due to factors such as infection
and physical activity. Additionally, the heterogeneity of
DKD is increasingly recognised, as reflected, for example,
by the disparity in DKD progression (fast versus slow
DKD progression) and by patients with declining kidney
function but normoalbuminuria. For example, 51% of par-
ticipants in the UK Prospective Diabetes Study whose
eGFR declined below 60ml/min/1.73m2 had normoalbu-
minuria [7]. This heterogeneity in DKD highlights the
need for novel biomarkers and a more personalised
medicine-based approach to managing DKD.
The fundamental aim of the Biomarker Enterprise to
Attack DKD (BEAt-DKD) consortium is to increase our
understanding of the pathogenesis and heterogeneity of
DKD, enabling the identification of novel biomarkers
and treatment targets, to facilitate a more personalised
medicine-based approach to managing DKD and in-
crease the efficiency of clinical trials [8].
Imaging biomarkers for DKD
Cross-sectional imaging, in particular MRI and US, is
increasingly proposed as an alternative source of
biomarkers to inform chronic kidney disease (CKD)
management [9, 10]. An important example is the quali-
fication by the Food and Drug Administration (FDA)
and the European Medicines Agency (EMA) of Total
Kidney Volume (TKV) as a prognostic enrichment bio-
marker for Autosomal Dominant Polycystic Kidney
Disease (ADPKD) – one of only a handful of clinical bio-
markers approved by the FDA so far [11, 12]. In recent
years the interest is increasingly moving towards ad-
vanced MRI and US techniques that are sensitive to
structural and functional tissue characteristics such as
perfusion, oxygenation, blood flow, glomerular filtration,
tubular flow, fibrosis, inflammation, metabolism and tis-
sue composition. Additional utility derives from the fact
that these characteristics can be measured separately for
left and right kidney and for cortex and medulla, and
that they can characterise functional and structural het-
erogeneity within those areas.
A number of preclinical and single-centre clinical stud-
ies have indicated a potential utility of MRI and US bio-
markers in DKD specifically. For instance, US-based
measurements of kidney volume have suggested that kid-
ney enlargement is associated with poorer outcomes in
early and advanced DKD, despite the often better GFR of
larger kidneys [13–15]. A possible explanation is that
hypertrophy indicates a sustained state of primary or sec-
ondary hyperfiltration and associated damage due to intra-
glomerular pressures. A mechanistic study suggested that
the MRI method BOLD (Blood Oxygenation Level
Dependent MRI) can highlight areas at risk of ischemic
damage due to oxygen depletion after sustained hyperfil-
tration [16], and recent clinical studies have confirmed
that the BOLD signal is predictive of CKD progression
[17, 18]. Some biomarkers derived from diffusion-
weighted MRI are sensitive to renal fibrosis [19, 20], can
identify microstructural changes after sustained hyperfil-
tration [21], and can potentially detect disease progression
earlier than eGFR [22]. Kidney perfusion can also be mea-
sured with MRI and has shown a correlation with eGFR in
DKD [23]. Other non-renal imaging biomarkers charac-
terising general risk factors for diabetes and its associated
complications may be relevant in this context as well and
can easily be measured in the same MRI scan session,
such as liver and pancreatic fat fraction [24].
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iBEAt study aims and objectives
The aim of iBEAt is to evaluate the utility of imaging
biomarkers in DKD in a large cohort of heterogeneous
T2D patients, in the early stages of DKD where there is
high potential for effective interventions to slow the rate
of DKD progression.
The key hypotheses are that (1) imaging biomarkers of
DKD provide additional information on the pathogenesis
and histological and clinical heterogeneity of DKD com-
pared to biomarkers sourced from blood or urine sam-
ples or physical exams, and that (2) changes in imaging
biomarkers precede increases in albuminuria and decline
in kidney function as measured by eGFR slope. As a
result, we expect imaging biomarkers to improve the
identification of DKD patients at risk of rapid decline in
kidney function, either when used alone or combined
with clinical data or biological fluid biomarkers.
An additional aim of the iBEAt study is to establish a
biobank of biological samples (blood- and urine-based)
from well-characterised patients not only for use within
the BEAt-DKD programme but also for future DKD col-
laborative studies with scientists outside BEAt-DKD.
This will facilitate biomarker discovery studies using
novel blood- and urine-based biomarkers and may serve
as the foundation for a comprehensive multi-scale phe-
notyping strategy linking data from blood, urine, tissue,
microvascular assessments, imaging, physical measure-
ments and medical histories.
The specific study objectives are:
 Primary objective: To examine whether renal
imaging biomarkers are associated with severity of
DKD as defined using classical biomarkers of DKD,
albuminuria and eGFR, in individuals with T2D and
eGFR ≥ 30 ml/min/1.73m2.
 Secondary objective: To examine whether renal
imaging biomarkers at baseline are associated with
changes in renal function over time as measured by
eGFR slope over a subsequent 3-year period.
Overview of iBEAt study design and organisation
iBEAt is a prospective observational study that will enrol
500 participants with T2D and eGFR greater than 30
mL/min/1.73m2 across multiple European centres.
A schematic overview of the study assessments is pre-
sented in Table 1. At baseline, medical histories will be
collected for each participant and they will undergo
comprehensive renal imaging (MRI and US), biological
sample collection (blood and urine) and physical mea-
surements. They will then be invited back annually for 3
years, where all measurements except the imaging will
be repeated.
The organisation of iBEAt is shown in Fig. 1. The
study is led by the coordinating centre in Sheffield with
a co-lead in Exeter and a study manager in Michigan.
Currently there are 5 recruiting centres (University of
Leeds, University of Exeter Medical School, University of
Bari, University of Bordeaux and University of Turku), a
central laboratory (Lund University) and a central data
repository (Swiss Institute of Bioinformatics (SIB)). Uni-
versity of Sheffield is the central imaging processing and
quality assurance (QA) site, with support from Antaros
Medical (Sweden) for biomarkers of body composition.
All ethical and relevant local approvals are in place at
each recruiting site. As a BEAt-DKD work package the
study is supported by the BEAt-DKD consortium Steer-




The iBEAt study will recruit participants with a diagno-
sis of T2D, eGFR greater or equal to 30 mL/min/1.73m2,
aged between 18 and 80 years, who are able to give in-
formed consent, and do not satisfy any of the exclusion
criteria. The exclusion criteria are listed in Table 2 (see
also additional file 3.0).
iBEAt will recruit across the A1-A3 albuminuria range
(normo-, micro- and macroalbuminuria) and the G1-G3
eGFR range (G1: ≥90; G2: 60–89; G3: 30–59ml/min/
1.73m2). In line with the National Kidney Foundation
guidelines [25], albuminuria will be classified using two
independent values of ACRs measured within a 3-month
period, and a third if the classification differs between
the first two samples. We define normo-, micro- and
macro-albuminuria as an ACR of < 2.5, 2.5–25, > 25 mg/
mmol for men, respectively, and as ACR < 3.5, 3.5–35, >
35mg/mmol for women, respectively.
Participants are enrolled in the study following
provision of written informed consent. Eligibility criteria
can be checked via medical records or by performing
additional assessments if no data available (e.g. eGFR). If
no ACR measurement is available from the previous 3




Participants are required to be on stable diabetes and
hypertension related treatment (though dose changes to
current medications are allowed) for the 3 months prior
to study assessments. Study assessments will be per-
formed in the morning following an overnight fast (> 8
h). Medications may be withheld or altered on the day
of the study visit to ensure participant wellbeing (e.g.
omitting morning insulin injection to maintain blood
glucose levels) and integrity of the study. The study visit
will include a checklist to record the adherence to
Gooding et al. BMC Nephrology          (2020) 21:242 Page 3 of 11
instructions (additional file 3.1). A point of care glucose
measurement will be performed upon participant arrival
and the visit will be cancelled if glucose levels are below
3.5 mmol/L or if the participant reports a symptomatic
hypoglycaemic event on the morning of the visit. If the
visit goes ahead, blood samples will be taken first. All
other assessments are performed following a standar-
dised meal of 2 slices brown bread, butter and a glass of
water (250 mL).
MRI biomarkers
Fifty nine primary MRI biomarkers will be recorded (see
additional file 1.1 for a full list), characterising general
body composition (e.g. visceral fat volume, pancreatic
and liver fat fraction), renal morphology (e.g. parenchy-
mal volume, cortical thickness), renal tissue structure
(e.g. MR relaxation times, apparent water diffusion coef-
ficient), renal hemodynamics (e.g. cortical perfusion,
renal artery blood flow), filtration (e.g. single-kidney
Table 1 Overview of the study showing type of data collected (rows) for each time point (columns)
Protocol Details Screening Baseline Year 1 Year 2 Year 3
Time Window Day 0 0-3 m 1y ± 3m 2y ± 3m 3y ±3 m
Informed Consent X
Demographics X
Clinical Information X X X X
Local lab value collection X X X X X
Blood Collection (including DNA and RNA) X X X X
Urine Collection (random) X
Urine Collection (1st morning & additional void) X X X X
MRI X
US X
y year, m month
Fig. 1 Overview of study organisation. iBEAt study organigram showing central roles (grey ellipse) and recruiting sites with ancillary studies
(circles). BMs = biomarkers; QA = quality assurance; RBF = renal blood flow; PET = Positron-emission tomography; SIB = Swiss Institute of
Bioinformatics; T1D = type 1 diabetes; Umich = University of Michigan
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GFR, filtration fraction). All MR scanning is performed
at 3 T on Siemens, Philips and General Electric scanners.
MRI data are uploaded on a central XNAT database
hosted by SIB and quality controlled within 48 h by the
central processing site.
The MRI protocol takes approximately 1 h and 10mins
and involves the injection of a quarter dose of clinical
macrocyclic MRI contrast agent. The protocol was first
developed on the reference Siemens scanner in Leeds
using an iterative optimisation guided by the NIST (Na-
tional Institute of Standards and Technology) phantom
and healthy volunteers. The resulting final protocol was
then characterised on each MRI vendor using a repeat-
ability study in healthy volunteers to determine within-
site variability (5 volunteers with 4 scans each). The
NIST phantom is scanned at regular intervals in all sites
to check for between-site calibration. Full details of the
MRI acquisition protocol on the 3 T Siemens reference
scanner in Leeds can be found in additional file 1.2.
Renal ultrasound
Kidney size will be non-invasively determined from lon-
gitudinal and transversal images of each kidney. Resistive
index (RI), indicator of the resistance to flow within the
kidney, will be determined from three measurements in
each kidney (upper, mid and lower poles). The mean of
the three measurements will represent RI for each re-
spective kidney. A list of US biomarkers is provided in
the additional file 3.7 and the Standard Operating Proce-
dures (SOPs) for US scanning are in additional file 1.3.
Blood and urine sampling
Fasting blood samples (~ 70ml designated for iBEAt
central requirement) will be collected from each partici-
pant for participant characterisation and biomarker ana-
lysis. Glycated haemoglobin (HbA1c), full blood count
and fasting glucose assessments will be performed locally
(additional file 3.4). The remaining plasma and serum
samples will be processed and stored following a stan-
dardised protocol (see additional files 2.1-2.3). A first
morning urine void and one additional morning void
(same day) are collected by all participants. A small pro-
portion of the first morning void is sent to the local la-
boratories for ACR assessment. The remainder of the
first morning and second void are then processed and
stored following a standardised protocol (see additional
files 2.1-2.3).
The standardised sample collection and processing
protocol, informed by PROVALID and NEPTUNE trials
[26, 27], was developed to maximise the utility of stored
samples for future biomarker analysis (e.g. lipidomics,
RNA analysis, urinary vesicles and urinary sediment)
within BEAt-DKD and to form a biobank for future
DKD related studies. A separate check is performed to
confirm that all samples are collected and processed ac-
cording to protocol (additional file 3.8).
The central laboratory is located at the Clinical Re-
search Centre (CRC) facility in Malmö (University of
Lund). The central lab will prepare and distribute kits
with sample collection and processing materials for each
patient labelled and barcoded with their unique study
ID. Each kit comprises of 66 storage tubes per patient.
The samples will be temporarily stored at each recruit-
ing site, with regular shipments returning them to the
biobank in Malmö. Samples will be stored under secure
conditions and monitored with a dedicated electronic
sample tracking system (Laboratory Information Man-
agement Systems). A small volume of blood and urine
will be analysed at the central laboratory in Malmö for
known clinical biomarkers according to standardised
methods, e.g. renal function (serum creatinine, cystatin
C, potassium and albumin), lipid profile (total choles-
terol and sub-fractions, triglycerides) and c-reactive pro-
tein. The remainder will be stored for future analyses by
Table 2 List of iBEAt exclusion criteria (see also additional file 3.0)
Permanent dialysis Current metastatic malignancy
Renal transplantation Current malignancy with expected survival < study follow up period (4 years)
Known clinical history of urinary obstruction on renal US Melanomatous skin cancer < 5 years ago (fully resected melanoma > 5 years ago,
i.e. surgical cure, can be recruited)
Post-voiding residue over 100 ml, or pyelectasis Use of investigational drug within 1 month prior to screening
Known clinical history of aortic endoprothesis at the renal level Current pregnancy
Known current or clinical history of renal or urinary tract malignancy Use of antiretroviral medication
Biopsy proven non-diabetic primary renal disease History of Hepatitis B or Hepatitis C
Autosomal dominant polycystic kidney disease (APKD) Significant comorbidities with life expectancy of < 1 year
Cirrhotic liver disease or non-cirrhotic chronic liver disease where
alanine aminotransferase > 2 x upper limit of normal
Standard contrast enhanced-MRI exclusions (e.g. cochlear implant, aneurysm clips,
claustrophobia and known allergy to Gadolinium contrast)
Renal stones causing CKD Any other significant disease or disorder which, in the opinion of the investigators,
may either put the patient at risk because of participation in the study, or may
influence the result of the study, or the patient’s ability to participate in the study
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BEAt-DKD investigators. The samples will also remain
available for secondary research provided approval is
granted by the iBEAt steering committee.
Physical examination
The core physical examination assessments include
blood pressures (sitting and standing blood pressures)
and anthropometrics (height, weight, waist and hip cir-
cumference). See additional file 3.2 for details.
Medical history
A detailed medical history (including, for example,
current medications, smoking history and presence of
co-morbidities) is also collected. See additional files 3.3
and 3.6 for data fields that are captured.
Routine laboratory data
Routine local laboratory data will be captured from med-
ical records to aid in the interpretation of the results by
tracking temporal changes at a finer time scale than the
yearly follow-ups. Only laboratory values available for
clinical indication will be captured at this time. Add-
itional file 3.5 lists the data fields to be captured but
missing data from the local chart is not deemed a proto-
col violation.
Follow-up study assessments
The blood and urine collection, medical history and
physical examination will be repeated at 1, 2 and 3 years
(± 3 months) following study enrolment. For participants
who are unable to attend the local research centre for an
annual follow-up visit but are still willing to participate
in the study, an update on their medical history will be
collected via direct communication with the participant
and / or by accessing their available medical records.
Data management
Clinical images, associated data and metadata will be
stored using the XNAT platform (www.xnat.org) hosted
on the dedicated BEAt-DKD server at SIB. Clinical study
data will be managed using REDCap (www.project-redcap.
org), also installed on the dedicated BEAt-DKD server. All
variables will be recorded on iBEAt central case report
form (CRFs – see additional files 3.0-3.8) and uploaded
onto the central RedCap instance. It is envisaged that the
iBEAt clinical study will be set up as a federated node en-
abling remote analysis of the data generated in the future,




There are insufficient a priori data available to perform a
reliable formal power calculation for this study. Thus, a
more pragmatic approach was adopted, with the sample
size taking into account the feasibility aspects of the
study, for example, the number of imaging facilities and
the estimated rate of recruitment in each centre. This
produced a target population of 500 patients, which will
result in the largest quantitative imaging DKD study, to
date, both in terms of patient numbers and regarding
patient follow-up. Participants will be recruited across
various stages of DKD, as measured by ACR (A1, A2,
A3) and eGFR (G1 + G2, G3). This will produce a het-
erogeneous population enabling the evaluation of the as-
sociations between imaging biomarkers and DKD in
T2D patients.
Statistical analysis plan
Descriptive statistics of all covariates across the study
centres will assess the bivariate relationships between
sets of related covariates. A cross-sectional analysis will
be performed using data collected at baseline, as well as
a longitudinal analysis using the imaging data collected
at baseline and blood and urine markers collected annu-
ally. Given the large number of covariates in the study, a
variable selection and regularisation method such as
LASSO [28] or the elastic net regularisation [29] will be
used. Modelling will use linear models for the cross-
sectional analyses, and linear mixed effects models for
the longitudinal analysis. The analyses will be performed
separately in each ACR / eGFR stratum, and the model-
ling of the whole cohort will account, whenever possible,
for differences in potential associations across the strata.
We will adjust for multiple comparisons as needed. If
any renal imaging biomarkers are identified as promising
early markers of DKD progression, they will be used in
risk prediction. Their predictive accuracy as measured
by prediction error, receiver operating characteristics
curve (ROC) and the area under the ROC (area under
the curve, AUC) will be evaluated using cross-validation.
A conservative approach will be adopted in all analyses,
for example, limiting the number of models fitted and
statistical tests performed. All analyses will be treated as
exploratory and hypotheses generating, rather than hy-
pothesis testing.
Ancillary studies
Building on the strengths and interests across the iBEAt
participating centres, six ancillary studies have been in-
corporated within the central iBEAt study. Participants
taking part in the ancillary studies will be recruited from
the central iBEAt study at the relevant sites.
Ancillary study 1
To examine whether MRI and US based imaging bio-
markers correlate with histopathological markers of
DKD and discriminate different renal lesions in this T2D
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cohort. For this ancillary study, led by Bari University,
iBEAt participants will undergo a renal tissue core biopsy.
All biopsies will be digitalised and characterised by light
microscopy (hematoxylin-eosin, periodic acid-Schiff, silver
methenamine, and Masson’s trichrome), immunofluores-
cence microscopy (with the use of antisera against IgG,
IgM, IgA, C3, C4, C1q and fibrinogen) and electron mi-
croscopy. Glomerular and vascular lesions, interstitial cell
infiltrate, fibrosis and tubular atrophy will be quantified to
classify patients accordingly [30]. Samples will also be
processed and stored for later biomarker discovery. The
procedures for processing, storing and capturing meta-
data regarding the renal biopsy tissue are described in
more detail in additional file 4.0.
Ancillary study 2
To examine whether MRI-based measurements of renal
blood flow correlate with H2O
15-positron emission tom-
ography (PET), considered to be a reference measure-
ment. For this ancillary study, led by Turku University, a
direct comparison of MRI and PET-based measurements
of renal blood flow will be performed in a cohort of
iBEAt participants. Renal perfusion will be assessed dur-
ing hyperaemia with both systems.
Ancillary study 3
To validate automated or semi-automated processing of
multiparametric renal MRI. In its current form the gen-
eration of biomarkers from complex functional MRI
scans involves significant manual intervention as well as
automated but slow iterative optimisation methods. In
this study, led by Sheffield University, a subset of the
iBEAt data will be used as training data to develop an
ideally automated approach for image processing, which
will then be validated on the remaining test data against
the manual results.
Ancillary study 4
To investigate the longitudinal changes in MRI and US
based biomarkers, compare them against changes in
eGFR and other known markers, and determine whether
changes in imaging biomarkers precede DKD progres-
sion as assessed by eGFR decline. For this study, per-
formed by the Universities of Bordeaux and Exeter, a
cohort of 100 patients will receive repeat MRI and US
after 2 years, and changes in imaging biomarkers over
that period will be correlated against changes in eGFR
and other assessments.
Ancillary study 5
To examine whether the glycocalyx, microvascular func-
tion and structure (retinal and skin) are (1) altered in
microalbuminuria (2); associated with DKD progression
as assessed by eGFR decline and (3) associated with
novel MRI and US imaging DKD biomarkers. For this
study, led by Exeter University, iBEAt participants will
also undergo comprehensive microvascular assessments
(including non-invasive estimation of sublingual endo-
thelial glycocalyx integrity, retinal vascular oxygenation
and skin maximum hyperaemia) at baseline and at 2
years follow-up.
Ancillary study 6
A pilot study to examine whether the findings in T2D
can be extrapolated to Type 1 diabetes. In this ancillary
study, led by Bordeaux University, a cohort of 50 pa-
tients with Type 1 diabetes for 15 years or more will be
assessed using the same procedures as the Type 2 cohort
and observed findings / trends will be compared across
the two populations.
Patient and public involvement
Patient and public involvement and engagement is a sig-
nificant component of the iBEAt study. Potential partici-
pants have played an important role in iBEAt, reviewing
the protocol to ensure the feasibility of the study design
(core and ancillary studies) as well as contributing to the
development of patient facing documents (e.g. patient
information sheets), ensuring that they are clear and in-
formative. Participants within the iBEAt study will play
an integral role in the dissemination of the study results
to the wider, non-expert population. Within the BEAt-
DKD consortium discussions with patient representa-
tives, ranging from experienced patient advocates to
iBEAt participants, will help inform how research from
the BEAt-DKD consortium is taken forward to imple-
ment a more precision medicine based approach in
DKD into clinical practice; for example, validation and
qualification of new biomarkers by regulatory agencies,
optimising clinical study design and integration in the
regulatory process of drug registration. Indeed, this has
already commenced with an iBEAt participant and other
patient representatives attending the 2nd BEAt-DKD
Stakeholders’ symposiums in April 2019 [31].
Discussion
Quantitative and functional imaging of the kidney has
been an active topic of research in the MRI physics and
radiology community for over two decades [32], but the
last few years have seen an explosive growth in clinical
interest. The first international meeting on functional
renal MRI was held in 2015 and attendance has been in-
creasing steadily in subsequent meetings [33–35]. In
2017, a pan-European network of researchers in renal
MRI (www.renalmri.org) was funded for 4 years by the
European Cooperation in Science and Technology
(www.cost.eu). In 2018, Nephrology Dialysis Transplant-
ation published a special issue on renal MRI with a
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clinical position statement supported by over 30 authors
including leading European nephrologists [9]. In the
same year, in the US, the National Institute of Diabetes
and Digestive and Kidney Diseases (NIDDK) at the
National Institutes of Health (NIH) conducted a work-
shop on renal imaging to review the state-of-the-art and
plan potential future endeavours [7]. Also in 2018, the
UK Renal Imaging network (UKRIN) received a 3-year
partnership grant to create a national infrastructure for
quantitative renal MRI. In 2020, UKRIN has received
funding for a 10 year cohort study in 500 CKD patients
starting 1 sept 2020 (AFiRM study; principal investiga-
tor: Nick Selby, University of Nottingham).
iBEAt setup started in September of 2016 and is the
first study to respond to the clinical need for systematic-
ally collected evidence at a larger scale and across insti-
tutions, with well-validated methods linking up the
imaging findings with other sources of data so the added
value can be identified. In that sense, iBEAt is inspired
by the landmark study CRISP (Consortium for Radio-
logic Imaging Studies of Polycystic Kidney Disease) [36]
- the first multi-centre cohort study exploring a quanti-
tative MRI biomarker (TKV) in CKD and a foundation
for the aforementioned FDA qualification of TKV. Like
CRISP, iBEAt has built in a technical validation phase of
the imaging biomarkers by including a repeatability
study on all scanner types deployed in iBEAt, and by
calibrating between-scanner differences through a travel-
ling test object developed by the National Institute of
Standards and Technology [37]. Also following the ex-
ample of CRISP, iBEAt is committed to sharing the tech-
nical details of its imaging protocols and expertise in
image processing and quality assurance – not only to fa-
cilitate the cost and setup of future studies but also to
maximise alignment and future opportunities for pooling
the data.
The integration of the ancillary studies into iBEAt will
provide valuable information on the pathogenesis of
DKD and the clinical utility of these imaging biomarkers.
Crucially, they will explore the association of renal based
imaging biomarkers against histopathological markers
and different histological lesions of DKD, validating the
imaging biomarkers and substantiating their clinical util-
ity. MRI-based renal perfusion measurements will also
be validated against PET renal perfusion measurements.
The potential automation of the MRI image processing
will streamline a labour-intensive process, thereby in-
creasing the clinical applicability of the assessments. The
microvascular assessments, including the examination of
glycocalyx integrity and endothelial function, will pro-
vide invaluable information on the pathogenesis and het-
erogeneity of DKD, and may well aid the identification
of individuals with fast progressing DKD. For example,
we hypothesise that individuals with T2D and early signs
of perturbations to the glycocalyx will be at an increased
risk of DKD progression.
iBEAt has greatly benefitted in its setup from study
documents and standard operating procedures (SOPs)
provided by other investigators, in particular the PRO-
VALID [27] and NEPTUNE [26] studies. In turn, iBEAt
is committed to a “pay-it-forward” philosophy and will
aim to share its study documentation and procedures
widely for use by other investigators. iBEAt collaborators
are also committed to maximise the opportunities for
data sharing in order to increase the lifetime value of
their research data as assets for human health and to do
so timely, responsibly, with as few restrictions as pos-
sible, in a way consistent with the law, regulation and
recognised good practice. Beyond data, iBEAt will aim to
form a powerful resource for future biomarker discovery
sources by collecting a rich collection of blood and urine
samples in its central biobank. These will be made avail-
able for external investigators subject to formal applica-
tion and approval by the iBEAt Steering Committee.
After a 2-year setup period the first study participant
was recruited into iBEAt in October 2018. First results
on technical validation of MRI methods on the reference
scanner are expected at the end of 2020. The projected
deadline for recruitment was 1 September 2020 and first
results on the primary objective (cross-sectional analysis
of baseline data) were expected to be made public in
2021. Completion of follow-up data was expected in
September 2023, with results on the longitudinal analysis
expected to be submitted for publication in 2024. These
timelines will be affected by a pause in recruitment dur-
ing the COVID-19 pandemic, but at submission of this
manuscript (April 2020) the exact implications are not
yet clear.
Conclusion
There is an unmet need for biomarkers that can improve
prediction of renal functional decline in DKD. Imaging
based biomarkers have not yet been explored in this
context and may be complementary to standard clinical
markers. iBEAt, the largest DKD imaging study to date,
will explore this hypothesis and may provide valuable in-
sights into the progression and heterogeneity of DKD.
The results may contribute to a more personalised ap-
proach to the management of DKD.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s12882-020-01901-x.
Additional file 1: 1.1 MRI biomarkers. File type: PDF file. Title: List of
primary MRI biomarkers. Description: A table listing the biomarkers that
will be derived from the MRI data to address the primary objectives. 1.2
MRI acquisition protocol. PDF file. MRI acquisition protocol (reference
scanner). MRI sequence parameters for the iBEAt protocol on the
Gooding et al. BMC Nephrology          (2020) 21:242 Page 8 of 11
reference scanner (Siemens 3 T). 1.3 Renal ultrasound SOP. PDF file.
Ultrasound Standard Operating Procedures. Standard operating
procedures for Ultrasound scanning in iBEAt.
Additional file 2: 2.1 Biofluid collection SOPs. PDF file. Biofluid
collection protocol. The protocol for the collection of blood and urine
samples within iBEAt. 2.2 SOPs Biofluid processing. PDF file. Biofluid
processing protocol. The protocol for processing blood and urine
samples within iBEAt. 2.3 Biofluid schematics. PDF file. iBEAt kit contents
and biofluid processing schematics. Schematics of iBEAt collection kits,
and processing and storage protocols for collected blood and urine
samples within iBEAt.
Additional file 3: 3.0 CRF Screening. PDF file. Study recruitment –
prescreening / screening. Clinical record form for prescreening /
screening data. 3.1 CRF Adherence Checklist. PDF file. Baseline visit (V1) –
adherence checklist. Clinical record form documenting participant
adherence to guidance for the baseline visit. 3.2 CRF Limited Clinical
Exam. PDF file. Limited Clinical Exam. Clinical record form for clinical
examination data including, for example, blood pressure, height and
weight. 3.3 CRF Medical and Family Hx. PDF file. Baseline (V1) – Medical
and family history V2. Clinical record form for medical and family history
(version 2). 3.4 CRF Local Study Labs. PDF file. Baseline (V1) – local study
labs. Clinical record form for laboratory measurements performed at
recruiting centre. 3.5 CRF Routine Labs. PDF file. Baseline visit (V1) – labs.
Clinical record form for documenting all available laboratory values in the
year prior to the baseline visit. 3.6 CRF Medications. PDF file. Medication
log. Clinical record form documenting all current medications. 3.7 CRF
Ultrasound. PDF file. Baseline visit (V1) – Ultrasound. Clinical record form
for the renal ultrasound measurements. 3.8 CRF Biosamples. PDF file.
Study biosamples. Clinical record form / checklist documenting what
biofluid samples were collected and processed for the iBEAt study.
Additional file 4: 4.0 Biopsy SOP. PDF file. Biopsy and pathology SOPs.
Protocol for storing and capturing meta-data regarding the renal biopsy
tissue for the iBEAt study. (EXE 543 kb)
Abbreviations
ACR: Albumin: creatinine ratio; ADPKD: Autosomal dominant polycystic
kidney disease; AUC: Area under the curve; BEAt-DKD: Biomarker Enterprise
to Attack Diabetic Kidney Disease; BMs: Biomarkers; BOLD: Blood
oxygenation level dependent; CKD: Chronic kidney disease; CRC: Clinical
research centre; CRF: Clinical record folder; CRISP: Consortium for Radiologic
Imaging Studies of Polycystic Kidney Disease; DKD: Diabetic kidney disease;
EFPIA: European Federation of Pharmaceutical Industries and Associations;
eGFR: Estimated glomerular filtration rate; EMA: European Medicines Agency;
FDA: Food and Drug Administration; HbA1c: Glycated haemoglobin;
iBEAt: Prognostic Imaging Biomarkers for Diabetic Kidney Disease;
IMI: Innovative Medicines Initiative; JDRF: Juvenile Diabetes Research
Foundation; MR: Magnetic resonance; MRI: Magnetic resonance imaging;
NIDDK: National Institute of Diabetes and Digestive and Kidney Diseases;
NIH: National Institute of Health; NIHR: National Institute of Health Research;
NIST: National Institute of Standards and Technology; PET: Positron-emission
tomography; QA: Quality assurance; RBF: Renal blood flow; RI: Resistive index;
ROC: Receiver operating characteristics curve; SOPs: Standard operating
procedures; SIB: Swiss Institute of Bioinformatics; TKV: Total kidney volume;
T1D: Type 1 diabetes; T2D: Type 2 diabetes; UMICH: University of Michigan;
US: Ultrasound
Acknowledgements
The authors thank Jo Brown and colleagues in the Leeds Biobanking and
Sample Processing Lab for helpful discussions informing study development
and Jacqueline Postma, project grant manager for BEAt-DKD, for invaluable
support during all phases of the study.
Authors’ contributions
SS and MFG are responsible for the concept of the study. All authors
contributed to the design of this study. SS, KS, VS, DS, IT, MM, MG, MFG, PN,
NK, MWS, LG, NG contributed to the iBEAt imaging (MRI and US) protocol
development. AZ, ADMA, MP, CL, KMG, NK, PP, JB, KT, CB, REB, PSG, DZ, HJLH,
MK, MG, LG, DA, AK, ACS, SS and MFG contributed to the development of
the biofluids collection and processing protocols, clinical assessment and
medical history data collection procedures. MM, AGH, MI, CL, MFG, KMG, FG,
SS, ACS, MK, KS, NK, PP, LG, NG, LG and AK contributed to data management
protocols, data and statistical analysis plans. LG, PP,MP, CL, MK, MFG
contributed to design of ancillary study 1; NK, PN, KM, SS, MFG, VC, KS
contributed to design of ancillary study 2; SS, DS and KS contributed to
design of ancillary study 3; NG, SS, ACS, KMG and MFG contributed to the
design of ancillary study 4; ACS, MG, MG, CB and MFG contributed to the
design of ancillary study 5; MFG, SS, NG, NK, ACS, KMG and AK contributed
to the design of ancillary study 6. KMG and ACS led on Patient Public
Involvement in the study protocol development. KMG, SS and MFG
assembled the manuscript. All authors critically reviewed and revised the
initial draft and approved the final version of the manuscript.
Funding
This project is principally funded by the Innovative Medicines Initiative 2
Joint Undertaking under grant agreement No 115974. This Joint Undertaking
receives support from the European Union’s Horizon 2020 research and
innovation programme and EFPIA with JDRF. This study receives additional
support (personnel support) by grants from the Swedish Heart and Lung
Foundation [20160872]; the Swedish Research Council [2018–02837;
EXODIAB 2009–1039]; the Swedish Foundation for Strategic Research (LUDC-
IRC 15–0067) to MFG; and the UK Medical Research Council (MR/R02264X/1)
and Kidney Research UK (RP55/2012) to SS. This project is also supported by
the National Institute for Health Research (NIHR) Exeter Clinical Research
Facility and the NIHR Leeds Clinical Research Facility. The views expressed
are those of the author(s) and not necessarily those of the NIHR or the
Department of Health and Social Care. The funding bodies, except for JDRF,
played no role in the design of the study and collection, analysis, and
interpretation of data and in writing the manuscript.
Availability of data and materials
iBEAt collaborators are committed to maximise the opportunities for data
sharing at study completion in order to increase the lifetime value of their
research data as assets for human health and to do so timely, responsibly, in
a way consistent with the law, regulation and recognised good practice.
Ethics approval and consent to participate
This study is being performed in accordance with the principles of the
Declaration of Helsinki and each recruiting centre has ethical approval from
their local Ethical review committee (Leeds/Sheffield: study was approved by
Yorkshire & The Humber - South Yorkshire Research Ethics Committee, ref.:
18/YH/0077; Exeter: study was approved by South West - Exeter Research
Ethics Committee, reference 18/SW/0061; Turku: study approved by Ethical
committee of Hospital District of South West Finland, reference: 123 /1801/
2017; Bordeaux: Study approved by CPP Est II, ref.: 18/581; Bari: study
approved by Independent Ethics Committee of the Policlinic Hospital in Bari,
ref.: 5760). Written, informed consent to participate in this study is being




This work forms part of the BEAt-DKD consortium that is funded by the IMI 2
Joint Undertaking that receives support from the European Federation of
Pharmaceutical Industries and Associations (EFPIA). BEAt-DKD EFPIA partners
that have contributed to the iBEAT study development are Astellas, AbbVie
and Novo Nordisk. JDRF also contributed to the iBEAT study design. AMDA
reports grants from Boehringer Ingelheim Pharma GmbH during the conduct
of the study. AZ reports non-financial support and other from Boehringer
Ingelheim Pharma GmbH during the conduct of the study. MG reports per-
sonal fees from Lilly and other from Sanofi Genzyme, outside of the submit-
ted work. DZ reports other from Fresenius, other from Boehringer Ingelheim,
other from Bayer, other from Mitsubishi Tanabe, other from Mundipharma,
other from Janssen, other from AbbVie, outside the submitted work. HJLH re-
ports other from Merck, other from Mitsubishi Tanabe, grants and other from
Janssen, other from Mundipharma, other from Gilead, grants and other from
AstraZeneca, grants and other from Abbvie, other from Retrophin, outside
the submitted work. MK reports grants from NIH, non-financial support from
University of Michigan, during the conduct of the study; grants from JDRF,
grants from Astra-Zeneca, grants from NovoNordisc, grants from Eli Lilly,
Gooding et al. BMC Nephrology          (2020) 21:242 Page 9 of 11
grants from Gilead, grants from Goldfinch Bio, grants from Merck, grants
from Janssen, grants from Boehringer-Ingelheim, outside the submitted work;
In addition, MK has a patent Biomarkers for CKD progression (encompassing
urinary EGF as biomarker of CKD progression) issued. DA reports other from
AbbVie, outside the submitted work. MFG reports non-financial support and
other from Boehringer Ingelheim Pharma GmbH, non-financial support and
other from JDRF International, non-financial support and other from Eli Lilly,
non-financial support and other from AbbVie, non-financial support and
other from Sanofi-Aventis, non-financial support and other from Astellas,
non-financial support and other from Novo Nordisk A/S, non-financial
support and other from Bayer AG, during the conduct of the study; personal
fees from Lilly, non-financial support and other from Novo Nordisk, non-
financial support and other from Pfizer, non-financial support and other from
Follicum, non-financial support and other from Abcentra, non-financial
support from Probi, non-financial support from Johnson & Johnson, outside
the submitted work. SS reports non-financial support from Siemens, during
the conduct of the study.
Author details
1Diabetes and Vascular Medicine, University of Exeter Medical School, Barrack
Road, Exeter EX2 5AX, UK. 2NIHR Exeter Clinical Research Facility, Royal
Devon and Exeter NHS Foundation Trust, Exeter, UK. 3Department of
Nephrology, University of Michigan, Ann Arbor, USA. 4Department of
Emergency and Organ Transplantation, Nephrology Unit, University of Bari
Aldo Moro, Bari, Italy. 5Department of Medicine, Division of Nephrology,
Turku University Hospital, Turku, Finland. 6Turku PET Centre, University of
Turku, Turku, Finland. 7Department of Clinical Sciences in Malmö, Lund
University Diabetes Centre, Lund University, Malmo, Sweden. 8Department of
Imaging, Infection, Immunity and Cardiovascular Disease, University of
Sheffield, Sheffield, UK. 9Astellas Pharma Europe B.V, Meppel, The
Netherlands. 10Leeds Teaching Hospitals NHS Trust, Leeds, UK. 11Department
of Renal Medicine and Renal Transplantation, Leeds Teaching Hospitals NHS
Trust, Leeds, UK. 12Department of Medical Physics, Division of Medical
Imaging, Turku University Hospital, Turku, Finland. 13Advanced Imaging
Centre, University of Leeds, Leeds, UK. 14Leeds Institute of Cardiovascular and
Metabolic Medicine, University of Leeds, Leeds, UK. 15Swiss Institute of
Bioinformatics, Lausanne, Switzerland. 16Novo Nordisk Research Center
Seattle, Inc., Seattle, USA. 17Leeds Institute of Medical Research at St James’s,
University of Leeds, Leeds, UK. 18The Drug Development Team, Leiden, The
Netherlands. 19Department of Clinical Pharmacy and Pharmacology,
University Medical Center Groningen, Groningen, The Netherlands.
20University of Groningen, Groningen, The Netherlands. 21Computational
Medicine and Bioinformatics, University of Michigan, Ann Arbour, USA.
22AbbVie, Scottsdale, USA. 23Service de Radiologie, CHU de Bordeaux,
Université de Bordeaux, Bordeaux, France.
Received: 13 May 2020 Accepted: 19 June 2020
References
1. Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, et al. Chronic
kidney disease: global dimension and perspectives. Lancet. 2013;382(9900):
12–8.
2. Zelnick LR, Weiss NS, Kestenbaum BR, Robinson-Cohen C, Heagerty PJ,
Tuttle K, et al. Diabetes and CKD in the United States population, 2009–
2014. Clin J Am Soc Nephrol. 2017;12(12):1984–90.
3. Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: challenges,
progress, and possibilities. Clin J Am Soc Nephrol. 2017;12(12):2032–45.
4. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes:
estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;
27(5):1047–53.
5. Svensson MK, Cederholm J, Eliasson B, Zethelius B, Gudbjörnsdottir S.
Albuminuria and renal function as predictors of cardiovascular events and
mortality in a general population of patients with type 2 diabetes: a
nationwide observational study from the Swedish National Diabetes
Register. Diabetes Vasc Dis Res. 2013;10(6):520–9.
6. Roscioni SS, Heerspink HJL, De Zeeuw D. The effect of RAAS blockade on
the progression of diabetic nephropathy. Nat Rev Nephrol. 2014;10(2):77–87.
7. Bilous R. Microvascular disease: what does the UKPDS tell us about diabetic
nephropathy? Diabet Med. 2008;25(Suppl. 2):25–9.
8. Lund University Diabetes Centre. Biomarker Enterprise to Attack Diabetic
Kidney Disease. 2019 . Available from: www.beat-dkd.org. [cited 2019 Aug 6].
9. Selby NM, Blankestijn PJ, Boor P, Combe C, Eckardt KU, Eikefjord E, et al.
Magnetic resonance imaging biomarkers for chronic kidney disease: a
position paper from the European Cooperation in Science and Technology
Action PARENCHIMA. Nephrol Dial Transplant. 2018;33(2):ii4–14.
10. Caroli A, Pruijm M, Burnier M, Selby NM. Functional magnetic resonance
imaging of the kidneys: where do we stand? The perspective of the European
COST Action PARENCHIMA. Nephrol Dial Transplant. 2018;33(2):ii1–3.
11. Thompson A. Clinical review of PKD outcomes consortium biomarker
qualification submissionle. 2015. Available from: https://www.fda.gov/media/
93159/download.
12. CDER-BiomarkerQualificationProgram. List of Qualified Biomarkers [Internet].
Available from: https://www.fda.gov/drugs/cder-biomarker-qualification-
program/list-qualified-biomarkers. Accessed 6 Aug 2019.
13. Mancini M, Masulli M, Liuzzi R, Mainenti PP, Ragucci M, Maurea S, et al.
Renal duplex sonographic evaluation of type 2 diabetic patients. J
Ultrasound Med. 2013;32(6):1033–40.
14. Zerbini G, Bonfanti R, Meschi F, Bognetti E, Paesano PL, Gianolli L, et al.
Persistent renal hypertrophy and faster decline of glomerular filtration rate
precede the development of microalbuminuria in type 1 diabetes. Diabetes.
2006;55(9):2620–5.
15. Rigalleau V, Garcia M, Lasseur C, Laurent F, Montaudon M, Raffaitin C, et al.
Large kidneys predict poor renal outcome in subjects with diabetes and
chronic kidney disease. BMC Nephrol. 2010;11(3).
16. Ries M, Basseau F, Tyndal B, Jones R, Deminière C, Catargi B, et al. Renal
diffusion and BOLD MRI in experimental diabetic nephropathy. J Magn
Reson Imaging. 2003;17(1):104–13.
17. Pruijm M, Milani B, Pivin E, Podhajska A, Vogt B, Stuber M, et al. Reduced
cortical oxygenation predicts a progressive decline of renal function in
patients with chronic kidney disease. Kidney Int. 2018;93(4):932–40.
18. Sugiyama K, Inoue T, Kozawa E, Ishikawa M, Shimada A, Kobayashi N, et al.
Reduced oxygenation but not fibrosis defined by functional magnetic
resonance imaging predicts the long-term progression of chronic kidney
disease. Nephrol Dial Transplant. 2020;35(6):964–70.
19. Friedli I, Crowe LA, Berchtold L, Moll S, Hadaya K, De Perrot T, et al. New
magnetic resonance imaging index for renal fibrosis assessment: a
comparison between diffusion-weighted imaging and T1 mapping with
histological validation. Sci Rep. 2016;6:30088.
20. Hueper K, Hartung D, Gutberlet M, Gueler F, Sann H, Husen B, et al.
Magnetic resonance diffusion tensor imaging for evaluation of
histopathological changes in a rat model of diabetic nephropathy. Investig
Radiol. 2012;47(7):430–7.
21. Lu L, Sedor JR, Gulani V, Schelling JR, O’Brien A, Flask CA, et al. Use of
diffusion tensor MRI to identify early changes in diabetic nephropathy. Am J
Nephrol. 2011;34(5):476–82.
22. Berchtold L, Crowe LA, Friedli I, Legouis D, Moll S, de Perrot T, et al.
Diffusion magnetic resonance imaging detects an increase in interstitial
fibrosis earlier than the decline of renal function. Nephrol Dial Transplant.
2020. https://doi.org/10.1093/ndt/gfaa007.
23. Mora-Gutiérrez JM, Garcia-Fernandez N, Slon Roblero MF, Páramo JA,
Escalada FJ, Wang DJJ, et al. Arterial spin labeling MRI is able to detect early
hemodynamic changes in diabetic nephropathy. J Magn Reson Imaging.
2017;46(6):1810–7.
24. Taylor R, Al-Mrabeh A, Zhyzhneuskaya S, Peters C, Barnes AC, Aribisala BS,
et al. Remission of Human Type 2 Diabetes Requires Decrease in Liver and
Pancreas Fat Content but Is Dependent upon Capacity for β Cell Recovery.
Cell Metab. 2018;28(4):547–56 e3.
25. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic
kidney disease: evaluation, classification, and stratification. Am J Kidney Dis.
2002;39(2 Suppl 1):S1–S266.
26. Gadegbeku CA, Gipson DS, Holzman LB, Ojo AO, Song PXK, Barisoni L, et al.
Design of the nephrotic syndrome study network (NEPTUNE) to evaluate
primary glomerular nephropathy by a multidisciplinary approach. Kidney Int.
2013;83(4):749–56.
27. Eder S, Leierer J, Kerschbaum J, Rosivall L, Wiecek A, De Zeeuw D, et al. A
prospective cohort study in patients with type 2 diabetes mellitus for
validation of biomarkers (PROVALID) - study design and baseline
characteristics. Kidney Blood Press Res. 2018;43(1):181–90.
28. Tibshirani R. Regression shrinkage and selection via the Lasso. J R Stat Soc
Ser B. 1996;58(1):267–88.
Gooding et al. BMC Nephrology          (2020) 21:242 Page 10 of 11
29. Zou H, Hastie T. Regularization and variable selection via the elastic net. J R
Stat Soc Ser B Stat Methodol. 2005;67(2):301–20.
30. Tervaert TWC, Mooyaart AL, Amann K, Cohen AH, TerenceCook H,
Drachenberg CB, et al. Pathologic classification of diabetic nephropathy.
J Am Soc Nephrol. 2010;21(4):556–63.
31. Pena M. Highlights from the BEAt-DKD symposium on precision medicine
in diabetic kidney disease. 2019. Available from: https://www.beat-dkd.eu/
download/BEAt-DKD_WP6_Newsletter_May_2019_by_Michelle_Pena.pdf.
32. Grenier N, Merville P, Combe C. Radiologic imaging of the renal
parenchyma structure and function. Nat Rev Nephrol. 2016;12(6):348–59.
33. Sourbron S, Grenier N. 1st International Meeting on Renal MRI. 2015.
Available from: https://sites.google.com/site/renalmriworkshop/. [cited
2019 Aug 18].
34. Pohlmann A, Seeliger E, Grosenick D, Waiczies S, Cantow K, Persson P, et al.
2nd International Meeting on Renal MRI. 2017. Available from: https://www.
mdc-berlin.de/renal. [cited 2019 Aug 18].
35. Francis S, Selby N, Taal M. 3d International Meeting on Renal MRI [Internet].
Available from: https://www.nottingham.ac.uk/research/groups/spmic/
research/uk-renal-imaging-network/3rd-renal-symposium/3rd-international-
symposium-on-functional-renal-imaging.aspx. Accessed 1 Nov 2019.
36. Grantham JJ, Torres VE, Chapman AB, Guay-Woodford LM, Bae KT, King BF,
et al. Volume progression in polycystic kidney disease. N Engl J Med. 2006;
354(20):2122–30.
37. Keenan KE, Ainslie M, Barker AJ, Boss MA, Cecil KM, Charles C, et al.
Quantitative magnetic resonance imaging phantoms: a review and the
need for a system phantom. Magn Reson Med. 2018;79(1):48–61.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Gooding et al. BMC Nephrology          (2020) 21:242 Page 11 of 11
